Below we have collated a list of key publications. Simply click on the title to access the publication abstract, and once in the abstract you can also click through to the full article. These publications have been selected for their relevance in the field of acute and advanced heart failure. These links will take you out of the Acute and Advanced Heart Failure Knowledge Centre into the main epgonline.org site.
Recently updated in June 2019 with a number of publications including: Management of cardiogenic shock in patients with acute coronary syndromes.
Find the rest of our selected publications below. For publications from 2016/17/18, scroll to the bottom of this page for the archive.
Levy B et al. Faculte de Médecine and Université de Lorraine, Nancy, France.
Curr Opin Crit Care 2019; [ePub Jun 3]. REVIEW
The authors consider dobutamine to be the first-line inotrope if norepinephrine fails to increase perfusion. Levosimendan can be used as a second-line inotrope, especially in patients treated with beta-blockers or in patients demonstrating catecholamine-related side effects. The role of levosimendan in this setting will be evaluated in the LevoHeartShock trial, which will include 634 patients in France.
Li J et al. Affiliated Hospital of Hebei University of Engineering, Handan, Heibei, China,
Eur Rev Med Pharmacol Sci. 2019;23(9):4027‒32. RANDOMISED CLINICAL TRIAL
Levosimendan was used in a trial comprising 80 patients. Plasma NT-proBNP levels were significantly reduced in the levosimendan group compared to the control group, which is a well-documented finding. 6-min walking distance was longer in the levosimendan group, but no baseline tests were performed. It seems as if the study was unblinded.
Sumanaru D et al. Hôpital Raymond-Poincaré, Garches, France.
Pediatr Cardiol. 2019; [ePub Feb 22]. CASE REPORT
Cardiomyopathy is a common feature in patients with Duchenne muscular dystrophy. A patient with Duchenne muscular dystrophy-associated cardiomyopathy was treated with 0.1 µg/kg/min of levosimendan for 8 hours. Both left ventricular ejection fraction and the uniformity of heart wall motion was substantially improved.
Metra M et al. University and Civil Hospital of Brescia, Brescia, Italy.
Card Fail Rev. 2019;5:5‒8. COMMENTS / REVIEW
It is only briefly mentioned that intermittent levosimendan administration has been associated with favorable effects on natriuretic peptides, quality of life and possibly hospitalisations.
Rathod KS et al. Barts Health NHS Trust and Queen Mary University of London, London, UK.
Br J Hosp Med. 2019;80:204‒10. REVIEW
Although the experience with levosimendan in this clinical setting is limited, some data indicate that levosimendan can improve haemodynamics when combined with catecholamines, to maintain adequate perfusion pressures. An expert review paper (Nieminen et al. 2016) recommends its use in combination with noradrenaline in patients with cardiogenic shock related to acute coronary syndromes.
Trambaiolo P et al. Sandro Pertini Hospital, Roma, Italy.
Int J Cardiol. 2019 [ePub Apr 17]. RETROSPECTIVE UNCONTROLLED TRIAL
Ventriculo-arterial coupling (VAC) reflects the relationship between myocardial contractility and arterial afterload. 48 levosimendan-treated patients were included in the study. VAC was measured using non-invasive methods. Levosimendan significantly increased stroke volume and ejection fraction, and VAC was slightly reduced (not statistically significantly). Baseline VAC seemed to predict mortality, but the number of patients was too small to enable definite conclusions.
Moltrasio M et al. Centro Cardiologico Monzino, Milan, Italy.
Eur Heart J Case Rep. 2019;3:1‒4. CASE REPORT
The patient was given 0.05 µg/kg/min of levosimendan for 48 hours. Levosimendan rapidly reverted cardiogenic shock, acute pulmonary edema and mitral regurgitation, contributing to a persistent clinical stabilization. The patient was discharged after 15 days.
Click the links below to view previous publications that have been featured here.2016 2017 2018